Tags : ravulizumab-cwvz


Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in

Shots: The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS, receiving dose based on their weight varying upto 3,600 mg for 2 years P-III study results: reduction in thrombocytopenia in 83.9% patients; reduction in hemolysis in 76.8% patients; improved kidney function in 58.9% patients; No case of meningococcal infection observed; […]Read More

Biosimilars Regulatory

Alexion’s Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal

Shots: The approval is based on P-III study results assessing of Ultomiris (IV qw, q8w) vs Soliris in 441 patients who were not treated with inhibitors or Soliris with patiparoxysmal nocturnal hemoglobinuria (PNH) The study demonstrated a non-inferiority data showing biosimilarity of Ultomiris to Soliris q2w with safe and well tolerated profile Ultomiris (ravulizumab-cwvz) is a […]Read More